Claims
- 1. A compound of the formula ##STR103## wherein: R.sup.1 is hydrogen, alkyl, cycloalkyl, cycloalkyl substituted by alkyl or hydroxyl, 2- or 3-tetrahydrofuranyl, 3-tetrahydrothienyl 1,1,-dioxide, cycloalkyl-alkyl, carboxyalkyl, carbo-lower-alkoxy-alkyl, dialkylaminoalkyl, phenyl-lower-alkyl, phenyl-lower-alkyl in which the phenyl ring is substituted in the 2, 3, or 4-position by one or two substituents, the same or different, selected from the group consisting of amino, halogen, alkyl, carboxyl, carbo-lower-alkoxy, carbamoyl, NHSO.sub.2 -(quinolinyl), nitro and cyano:
- R.sup.3 is hydrogen, lower-alkyl, phenyl-lower-alkyl, lower-alkoxyphenyl-lower-alkyl, dilower-alkoxy-phenyl-lower-alkyl, pyridyl-lower-alkyl, cycloalkyl-lower-alkyl, phenylamino, dialkylamino, halogen, trifluoromethyl, lower-alkylthio, cyano or nitro; and
- R.sup.6 is a five or six membered heterocyclic ring containing from one to two nitrogen atoms, substituted--or unsubstituted--at any available carbon atom by one or two substituents, the same or different, selected from the group consisting of lower-alkyl, halogen, lower-alkoxy, cycloalkyloxy, 4-morpholinyl, lower-alkoxy-lower-alkoxy, hydroxy, imidazolyl, oxo and 4-morpholinyl-lower-alkoxy; or at any available nitrogen atom by lower-alkyl, lower-alkanoyl, or trifluoroacetyl; or a pharmaceutically acceptable acid-addition salt thereof.
- 2. A compound according to claim 1 wherein:
- R.sup.1 is alkyl, cycloalkyl, cycloalkyl-alkyl, carboxyalkyl, carbo-lower-alkoxy-alkyl, phenyl-lower-alkyl, phenyl-lower-alkyl in which the phenyl ring is substituted in the 2, 3 or 4-position by one or two substituents, the same or different, selected from the group consisting of amino, halogen, alkyl, carbo-lower-alkoxy, carbamoyl, NHSO.sub.2 -(quinolinyl), and nitro; and
- R.sup.3 is lower-alkyl, phenyl-lower-alkyl, lower-alkoxyphenyl-lower-alkyl, dilower-alkoxy-phenyl-lower-alkyl, pyridyl-lower-alkyl, cycloalkyl-lower-alkyl, phenylamino, dialkylamino, trifluoromethyl, or lower-alkylthio.
- 3. A compound according to claim 2 wherein R.sup.6 is selected from the group consisting of: ##STR104## which can be attached through any available ring carbon atom for nitrogen atom to position six of the pyrazolo[3,4-d]pyrimidin-4-one;
- R.sup.7 is hydrogen, lower-alkyl, lower-alkanoyl or trifluoroacetyl, and
- R.sup.8 is one or two substituents, the same or different, selected from the group consisting of hydrogen, lower-alkyl, halogen, lower-alkoxy, cycloalkyloxy, 4-morpholinyl, lower-alkoxy-lower-alkoxy, hydroxy, imidazolyl and 4-morpholinyl-lower-alkoxy which can be attached to any available ring carbon atom; or a pharmaceutically acceptable acid-addition salt thereof.
- 4. A compound according to claim 3 wherein R.sup.6 is: ##STR105##
- 5. A compound according to claim 4 wherein R.sup.6 is: ##STR106##
- 6. A compound according to claim 5 wherein R.sup.6 is 4-pyridyl and R.sup.8 is one or two substituents, the same or different, selected from the group consisting of hydrogen, lower-alkyl, halogen, lower-alkoxy, cycloalkyloxy, lower-alkoxy-lower-alkoxy, imidazolyl and 4-morpholinyl-lower-alkoxy.
- 7. A compound according to claim 6 wherein R.sup.1 is alkyl, cycloalkyl or substituted phenyl-lower-alkyl; and R.sup.3 is lower-alkyl, trifluoromethyl, phenyl-lower-alkyl, di-lower-alkoxy-phenyl-lower-alkyl, pyridyl-lower-alkyl, or cycloalkyl-lower-alkyl.
- 8. A compound according to claim 7 wherein R.sup.1 is tert-butyl or cyclopentyl.
- 9. A compound according to claim 8 wherein R.sup.3 is methyl, ethyl, trifluoromethyl, phenylmethyl, 3,4-dimethoxyphenylmethyl, 4-pyridylmethyl, or cyclohexylmethyl.
- 10. 1-Cyclopentyl-3-methyl-6-(4-pyridyl)pyrazolo[3,4-d]pyrimidin-4-one, according to claim 9.
- 11. 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)pyrazolo[3,4-d]pyrimidin-4-one, according to claim 9.
- 12. 1-Cyclopentyl-3-ethyl-6-(3-methoxy-4-pyridyl)pyrazolo[3,4-d]pyrimidin-4-one, according to claim 9.
- 13. 1-Cyclopentyl-3-trifluoromethyl-6-(3-ethoxy-4-pyridyl)pyrazolo[3,4-d]pyrimidin-4-one, according to claim 9.
- 14. A compound according to claim 4 wherein R.sup.6 is: ##STR107##
- 15. A compound according to claim 14 wherein R.sup.1 is alkyl, cycloalkyl or substituted phenyl-lower-alkyl; R.sup.3 is lower-alkyl, trifluoromethyl, phenyl-lower-alkyl, di-lower-alkoxy-lower-alkyl, pyridyl-lower-alyl, or cycloalkyl-lower-alkyl; and R.sup.6 is 4-piperidinyl, 1-acetyl-4-piperidinyl, 1-trifluoromethyl-4-piperidinyl or 2-oxo-4-pyridyl.
- 16. A compound according to claim 15 wherein R.sup.1 is cycloalkyl; and R.sup.3 is lower-alkyl.
- 17. A compound according to claim 16 wherein R.sup.1 is cyclopentyl; and R.sup.3 is methyl.
- 18. A compound according to claim 3 wherein R.sup.6 is ##STR108##
- 19. A compound according to claim 18 wherein R.sup.1 is alkyl, cycloalkyl or substituted phenyl-lower-alkyl; R.sup.3 is lower-alkyl, trifluoromethyl, phenyl-lower-alkyl, dilower-alkoxyphenyl-lower-alkyl, pyridyl-lower-alkyl, or cycloalkyl-lower-alkyl; and R.sup.6 is 1-imidazolyl.
- 20. A compound according to claim 19 wherein R.sup.1 is cycloalkyl; and R.sup.3 is lower-alkyl.
- 21. 1-Cyclopentyl-3-ethyl-6-(2-(1-imidazolyl)-4-pyridyl)pyrazolo[3,4-d]pyrimidin-4-one, according to claim 20.
- 22. A pharmaceutical composition comprising an antihypertensively effective amount of a compound according to claim 1 together with a pharmaceutically acceptable carrier or diluent.
- 23. A pharmaceutical composition comprising an antihypertensively effective amount of a compound according to claim 4 together with a pharmaceutically acceptable carrier or diluent.
- 24. A pharmaceutical composition comprising an antihypertensively effective amount of a compound according to claim 5 together with a pharmaceutically acceptable carrier or diluent.
- 25. A pharmaceutical composition comprising an antihypertensively effective amount of a compound according to claim 9 together with a pharmaceutically acceptable carrier or diluent.
- 26. A method of treating hypertension in a mammalian organism which comprises administering to said organism an effective amount of a composition according to claim 22.
- 27. A method of treating hypertension in a mammalian organism which comprises administering to said organism an effective amount of a composition according to claim 23.
- 28. A method of treating hypertension in a mammalian organism which comprises administering to said organism an effective amount of a composition according to claim 24.
- 29. A method of treating hypertension in a mammalian organism which comprises administering to said organism an effective amount of a composition according to claim 25.
Parent Case Info
This application is a division of application Ser. No. 07/859,770, filed Mar. 30, 1992, now U.S. Pat. No. 5,294,612, issued Mar. 15, 1994.
US Referenced Citations (7)
Foreign Referenced Citations (5)
Number |
Date |
Country |
463756 |
Jan 1992 |
EPX |
526004 |
Feb 1993 |
EPX |
937722 |
Sep 1963 |
GBX |
8800192 |
Jan 1988 |
WOX |
9306104 |
Apr 1993 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Hamilton et al, Journal Med. Chem. vol. 30, pp. 91-96 (1987). |
Burch,--J. Med. Chem. 1968, pp. 79-83. |
Miyashita et al, Heterocycles, 1990, p. 1309. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
859770 |
Mar 1992 |
|